Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Each Dose of Neo-Penotran® contains a combination of Metronidazole and Miconazole Nitrate in therapeutic concentrations for the local treatment of the treatment three main types of vaginal infections and mixed forms of vaginitis. More
Hyaluronan based gel for prevention and reduction of adhesion formation in the abdominal pelvic area More
pH maintenance, Spermicide, Microbicide Lubricant More
New Active Ingredient + Innovative Drug Delivery System = Business Success More
Researchers at the University of Western Ontario have developed a Pulmonary Drug Delivery Technology Suite comprised of two innovative inventions for the precision measurement and dispensing of micro fine, dry powders. More
Coupling drug substances with hydroxyethyl starch (HES) derivatives to improve pharmacokinetics and pharmacodynamics. More
Antroquinonol® is a non-toxic, highly effective cancer treatment agent, developed using natural organic chemistry. More
Comfortable, better distribution, "shower-head' Vaginal Applicator More
Phytohealth Corporation: PH3 (PHN031, PHN033) - For osteoporosis and diabetic vascular complications
Patented technology regarding new and safe mechanism with the active substance PH3 for the indications of osteoporosis and diabetic vascular complications. More
Novel agent for OAB treatment successfully passed Clinical Phase II More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Gender related medicine female
- Gender related medicine male
- Genito-urinary other
- Paget's disease
- Sexually transmitted diseases
- Urinary
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us